Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review

Szabo, Shelagh M.; Samp, Jennifer C.; Walker, David R.; Lane, Suzanne; Cline, Stephanie K.; Gooch, Katherine L.; Jimenez-Mendez, Ricardo; Levy, Adrian R.
September 2015
Annals of Hepatology: Official Journal of the Mexican Associatio;Sep/Oct2015, Vol. 14 Issue 5, p618
Academic Journal
Despite reports that mortality is increasing, overall case fatality due to hepatitis C virus (HCV) is thought to be low. Given the variability in published rates, we aimed to synthesize estimates of liver-specific case fatality and all-cause mortality in chronic HCV according to follow-up duration, sustained viral response (SVR) to treatment, and liver disease severity. A systematic review was conducted of studies published in English from 2003 to 2013, reporting liver-specific case fatality estimates from HCV-infected samples. Thirty-five eligible articles were identified; 26 also presented estimates of all-cause mortality. Among community-based samples, liver-specific case fatality ranged from 0.3% over 5.7 years to 9.2% over 8.2 years of follow-up; and of all-cause mortality, from 4.0% over 5.7 years, to 23.0% over 8.2 years of follow-up. Estimates were higher among clinic-based samples and those with more severe liver disease. Among treated patients achieving SVR, liver-specific case fatality was low: up to 1.4% over 11.5 years of follow-up among samples with any severity of liver disease. Estimates were higher among those without SVR: up to 14.0% over 10 years of followup among samples with any severity of liver disease, and higher still among samples with more severe liver disease. The proportion of deaths attributable to liver-specific causes ranged from 55 to 85% among those with severe liver disease. Published estimates of fatality are high among certain populations of chronic HCV patients, with liver-specific causes being an important contributor. Understanding current HCV mortality rates is important for quantifying the total burden of HCV disease.


Related Articles

  • Sero-epidemiologic study of hepatitis C virus infection in Fukuoka, Japan. Sata, Michio; Nakano, Hitoshi; Suzuki, Hiroshi; Noguchi, Seiji; Yamakawa, Yohsuke; Tanaka, Eisuke; Fukuizumi, Kunitaka; Tanaka, Kumi; Yoshida, Hiroshi; Tanikawa, Kyuichi; Sata, M; Nakano, H; Suzuki, H; Noguchi, S; Yamakawa, Y; Tanaka, E; Fukuizumi, K; Tanaka, K; Yoshida, H; Tanikawa, K // Journal of Gastroenterology;1998, Vol. 33 Issue 2, p218 

    We conducted an epidemiological study of 509 residents of H town, Fukuoka, Japan, to investigate the high mortality rate from liver disease. Antibodies to hepatitis C virus (HCV) (anti-HCV) were detected in 120 residents (23.6%); HCV RNA in 91 (17.9%), and hepatitis B surface antigen (HBsAg) in...

  • Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Iwasa, Yuko; Otsubo, Shigeru; Sugi, Orie; Sato, Keitaro; Asamiya, Yukari; Eguchi, Aya; Iwasaki, Tomihito; Matsuda, Nami; Kikuchi, Kan; Ikebe, Norisato; Miwa, Naoko; Kimata, Naoki; Uchida, Keiko; Uchida, Shigeharu; Nitta, Kosaku; Akiba, Takashi // Clinical & Experimental Nephrology;Feb2008, Vol. 12 Issue 1, p53 

    Although hepatitis C virus (HCV) infection is a persistent public health concern in hemodialysis patients, there seem to have been only a few reports on the prevalence of HCV at the start of hemodialysis. In this study we investigated whether patients starting on hemodialysis therapy are...

  • Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. Macías, Juan; Del Valle, José; Rivero, Antonio; Mira, José A.; Camacho, Ángela; Merchante, Nicolás; Pérez-Camacho, Inés; Neukam, Karin; Rivero-Juárez, Antonio; Mata, Rosario; Torre-Cisneros, Julián; Pineda, Juan A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2204 

    Objectives: To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy.

  • Alcoholic Liver Disease-Related Mortality in the United States: 1980–2003. Paula, Helga; Asrani, Sumeet K.; Boetticher, Nicholas C.; Pedersen, Rachel; Shah, Vijay H.; Kim, W. Ray // American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1782 

    OBJECTIVES:Data on temporal changes in alcoholic liver disease (ALD)-related mortality in the United States are lacking. This longitudinal assessment is important, given the divergent data on trends in worldwide ALD-related mortality, concerns for underestimation of mortality attributed to ALD...

  • Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Wakita, Takaji; Pietschmann, Thomas; Kato, Takanobu; Date, Tomoko; Miyamoto, Michiko; Zijiang Zhao; Murthy, Krishna; Habermann, Anja; Kräusslich, Hans-Georg; Mizokami, Masashi; Bartenschlager, Ralf; Liang, T. Jake // Nature Medicine;Jul2005, Vol. 11 Issue 7, p791 

    Hepatitis C virus (HCV) infection causes chronic liver diseases and is a global public health problem. Detailed analyses of HCV have been hampered by the lack of viral culture systems. Subgenomic replicons of the JFH1 genotype 2a strain cloned from an individual with fulminant hepatitis...

  • Passive Surveillance of Anti-Hepatitis C Virus Antibodies in Human Subjects of Four Medical Units of Balochistan, Pakistan. Mengal, Mohammad Alam; Abbas, Ferhat; Mengal, Mohammad Azam; Shafee, Muhammad; Babar, Shakeel; Mengal, Mohammad Aslam; Atique, Adnan // International Journal of Agriculture & Biology;Aug2012, Vol. 14 Issue 4, p107 

    Hepatitis C virus is a major public health problem and a causative agent of chronic liver disease worldwide. Hepatitis C virus infection is indolent and asymptomatic disease in human that can lead to liver cirrhosis and hepatocellular carcinoma. A cross sectional study was conducted in six...

  • The management of patients positive to hepatitis C virus antibody in Malta. Brincat, Anthea; Azzopardi, Neville; Deguara, Maria; Taliana, Kelly Mifsud; Rogers, Marilyn; Pocock, James // Malta Medical Journal;2013, Vol. 25 Issue 4, p72 

    Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease and hepatocellular carcinoma worldwide and is an important public health concern. A retrospective analysis of the demographics and management of patients who had a positive anti-HCV detected by enzyme...

  • EVALUAREA PRIN METODE NONINVAZIVE A FIBROZEI HEPATICE LA PACIENÅ¢II CU COINFECÅ¢IE VHC-HIV UTILIZATORI DE DROGURI PE CALE INTRAVENOASÄ‚. Lazăr, Ştefan; Chiriţă, Daniel; Oprea, Cristiana; Drăghici, Loredana; Obretin, Dana; Tudor, Nicoleta; Ceauşu, Emanoil // Romanian Journal of Infectious Diseases;2014, Vol. 17 Issue 3, p158 

    Introduction. Coinfection of the hepatic C virus with the human immunodeficiency virus (HIV) in intravenous drug users (UDI) represents an important public health problem because of the big and increasing number of patients and the diagnostic, monitoring and treatment related challenges....

  • All-Cause, Liver-Related, and Non-Liver-Related Mortality Among HCV-Infected Individuals in the General US Population. El-Kamary, Samer S.; Jhaveri, Ravi; Shardell, Michelle D. // Clinical Infectious Diseases;7/15/2011, Vol. 53 Issue 2, p150 

    Background. Liver-related mortality among those infected with hepatitis C virus (HCV) has been described, but little is known about non-liver-related mortality. Our objective was to determine HCV-associated all-cause, liver-, and non-liver-related mortality in the general US population. Methods....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics